WASHINGTON, July 7 — For the families who have watched a child or a loved one battle a blood cancer that just would not quit, the arrival of CAR-T therapy felt like a door opening where there had been only a wall. Since the first approval in the late summer of 2017, the Food and Drug Administration has now cleared six such therapies, each one a bespoke treatment made from a patient’s own immune cells.
The story began on August 30, 2017, when the FDA approved tisagenlecleucel, sold as Kymriah by Novartis, for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia. It was a landmark moment — the first CAR-T therapy ever authorized in the United States, and it targeted a disease that had left too many young patients with few options.
Just weeks later, on October 18, 2017, the agency approved axicabtagene ciloleucel — Yescarta, from Kite/Gilead — for adults with large B-cell lymphoma. Two approvals in two months. The field was moving fast.
The pace has not let up. On February 5, 2021, brexucabtagene autoleucel, or Tecartus, also from Kite/Gilead, was approved for mantle cell lymphoma.
A little over a year later, on February 28, 2022, ciltacabtagene autoleucel — Carvykti, developed by Janssen in partnership with Legend Biotech — won approval for multiple myeloma. Then, on March 15, 2024, lisocabtagene maraleucel, marketed as Breyanzi by Bristol-Myers Squibb, was approved for chronic lymphocytic leukemia and small lymphocytic lymphoma. Each of these approvals came with a serious caveat.
Because CAR-T therapy carries known risks — most notably cytokine release syndrome and neurotoxicity — the FDA requires that every product be covered by a Risk Evaluation and Mitigation Strategy, or REMS. That means hospitals and clinics must have special training and protocols in place before they can administer the treatment. It is a safety net, and it is non-negotiable.
The science behind these therapies is as elegant as it is complex. A patient’s T-cells are harvested, genetically engineered in a lab to recognize and attack cancer cells, and then infused back into the body.
The result is a living drug — one that can multiply and persist, hunting malignancy long after the initial infusion. But manufacturing a living drug at scale is no small feat. The FDA has issued guidance on manufacturing and quality control, including a 2023 draft guidance on potency assays for cellular therapy products.
These documents help ensure that each batch of CAR-T cells is consistent, potent, and safe — a critical concern when every dose is, in a very real sense, a custom product for a single patient. For the people behind these numbers — the researchers, the regulators, the clinicians, and above all the patients and their families — the story is one of steady, deliberate progress.
Each approval represents years of laboratory work, clinical trials, and careful review. Each one also represents a chance, where before there was often none. The field continues to evolve.
Researchers are exploring ways to make CAR-T cells more durable, to reduce side effects, and to extend the therapy to solid tumors, which have so far proven more resistant. The FDA’s regulatory framework will need to keep pace, balancing urgency with the rigor that patient safety demands. What began with a single approval in 2017 has grown into a pillar of modern cancer care.
For those who have been touched by these therapies — whether as patients, as family members, or as the scientists who made them possible — the progress is not abstract. It is deeply, personally real. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “FDA Approvals of CAR-T Therapies: 2017-2024 Timeline”, “description”: “WASHINGTON, July 7 — For the families who have watched a child or a loved one battle a blood cancer that just would not quit,…”, “datePublished”: “2026-07-07T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
